marijuana stocks news

Form 8-K for CANNABIS SCIENCE, INC.

24-Nov-2014

Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive AgreementOn November 20, 2014, Cannabis Science, Inc.(the “Company”), entered into an Amendment to a License Agreement (the “Amendment Agreement”) that it had entered into with Apothecary Genetics Investments LLC (“Apothecary”) on February 9, 2012 (the “Original Agreement”). The parties entered into the Amendment Agreement to amend certain terms that were contained in the Original Agreement. In the Amendment Agreement, the Company has agreed to issue Apothecary or its assigns 14,500,000 shares of restricted common stock of the Company and fund Apothecary a minimum of $150,000 up to a maximum of $300,000 in working capital per calendar quarter commencing in the quarter ending December 31, 2014. In exchange the Company will purchase and license two northern California production farms with a combined total of 51 acres and related equipment for cannabis cultivation and new product development. As a result of the acquisition, the Company is entitled to licensing fees and royalties, rights to assign assets and fees to affiliates and subsidiaries and ownership of all tangible assets such as land, facilities and equipment as well as new business ventures.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$CBIS Brings CS-TATI-1 to the FDA

Cannabis Science Brings CS-TATI-1 to the FDA with Historic Collaborative Drug Development…

The Green Organic Dutchman Holdings Ltd. (TGOD) (TGODF) and Caliper Foods Report Positive Results

The Green Organic Dutchman and Caliper Foods Report Positive Results from Pharmacokinetic…

Sundial Growers Inc.(SNDL) Files Early Warning Report Issued Pursuant to National Instrument 62-103

Sundial Files Early Warning Report Issued Pursuant to National Instrument 62-103 VLNCF…

$CARA Announces Successful Completion of Phase 1b Trial

Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V.…